Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Medication

Medication Recalls

Browse drug and medication recalls including prescription drugs, OTC medications, and supplements. Stay informed about pharmaceutical safety alerts.

Get alerts for medication RSS feed

Showing 741–760 of 1639 recalls

Filter by date, severity, state →

Ful-Glo (Nomax) – Impurity Specification Failure (2024)

Failed Impurities/Degradation Specifications: The Active Pharmaceutical Ingredient (API) used in the product is not being manufactured to the current USP monograph in regard to Unspecified Impurities.

Class IIModerate

FDAApr 19, 2024Nationwide• Nomax Inc

Amphotericin B Liposome (Sun Pharmaceutical) – Assay Issue (2024)

Out of specification for assay

Class IIModerate

FDAApr 19, 2024Nationwide• SUN PHARMACEUTICAL INDUSTRIES INC

Diltiazem Hydrochloride (Glenmark) – Dissolution Failure (2024)

Failed Dissolution Specifications

Class IIModerate

FDAApr 17, 2024Nationwide• Glenmark Pharmaceuticals Inc., USA

Prednisolone-Moxifloxacin-Bromfenac Solution (Imprimis) – Subpotent Drug (2024)

Subpotent Drug

Class IIModerate

FDAApr 10, 2024Nationwide• Imprimis NJOF, LLC

Epinephrine-Lidocaine HCl Solution (Imprimis) – Assay Specification (2024)

Out of specification for assay

Class IIILow

FDAApr 10, 2024Nationwide• Imprimis NJOF, LLC

Abilify 15mg Tablets (Otsuka) – Product Contamination (2024)

Cross Contamination with Other Products

Class IIILow

FDAApr 9, 2024Nationwide• Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Abilify 30mg Tablets (Otsuka) – Product Contamination (2024)

Cross Contamination with Other Products

Class IIILow

FDAApr 9, 2024Nationwide• Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Abilify 5mg Tablets (Otsuka) – Product Contamination (2024)

Cross Contamination with Other Products

Class IIILow

FDAApr 9, 2024Nationwide• Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Abilify 10mg Tablets (Otsuka) – Product Contamination (2024)

Cross Contamination with Other Products

Class IIILow

FDAApr 9, 2024Nationwide• Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.

Sapropterin Dihydrochloride Powder (Dr. Reddy's) – Sub-potent Drug (2024)

Sub-potent Drug; powder discoloration associated with decreased potency

Class IHigh

FDAApr 8, 2024Nationwide• Dr. Reddy's Laboratories, Inc.

Javygtor Oral Powder (Dr. Reddy's) – Sub-potent Drug (2024)

Sub-potent Drug; powder discoloration associated with decreased potency

Class IHigh

FDAApr 8, 2024Nationwide• Dr. Reddy's Laboratories, Inc.

ELV Control Herbal Supplement (World Green Nutrition) – Toxic Ingredient (2024)

FDA Analysis found product labeled as tejocote is actually yellow oleander, which is toxic to humans.

Class IHigh

FDAApr 3, 2024DE, OR• World Green Nutrition Inc.

Isotretinoin 40mg Capsules (Teva) – Superpotent Drug (2024)

Superpotent Drug: The 3-month stability result for assay was found to be above specification limit

Class IIModerate

FDAMar 28, 2024Nationwide• Teva Pharmaceuticals USA, Inc

Lansoprazole Capsules (NATCO) – Manufacturing Deviation (2024)

CGMP Deviations

Class IIModerate

FDAMar 27, 2024Nationwide• NATCO Pharma Limited

Diltiazem Extended-Release Capsules (Glenmark) – Dissolution Failure (2024)

Failed Dissolution Specifications: Out of Specification (OOS) was reported in test of dissolution at the 12th month time point in long term stability study.

Class IIModerate

FDAMar 26, 2024Nationwide• Glenmark Pharmaceuticals Inc., USA